<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="Research Article" dtd-version="1.0"><front><journal-meta><journal-id journal-id-type="pmc">iarjms</journal-id><journal-id journal-id-type="pubmed">IARJMS</journal-id><journal-id journal-id-type="publisher">IARJMS</journal-id><issn>2708-3594</issn></journal-meta><article-meta><article-id pub-id-type="doi">https://doi.org/10.47310/iarjms.2023.v04i01.042</article-id><title-group><article-title>Treatment Strategies in Early Rheumatoid Arthritis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><given-names>Devi</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><given-names>Rahul</given-names><surname>Ranta</surname></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><given-names>Ritika</given-names></name></contrib></contrib-group><aff-id id="aff-a" /><abstract>Evidence suggests that current Rheumatoid Arthritis (RA) treatment methods should prioritise early identification and diagnosis, followed by early introduction of DMARD medication. Early RA treatment-ideally less than three to six months after the onset of symptoms-improves the likelihood of reaching disease remission and lessens joint damage and disability. Utilising initial DMARD mono-or combination therapy with quick escalation to target low disease activity or remission is a viable approach, even though the ideal treatment plan for early RA is not yet known. The prevention of inflammatory joint illness and, thus, the prevention of disability, should be the ultimate goal of RA care.&amp;nbsp;</abstract></article-meta></front><body /><back /></article>